FLT3 and acute myeloid leukemia: Among the 356 cytogenetically normal (CN)-AML patients, 64 (18.0%) with an isolated NPM1 mutation were classified into the favorable-risk group and excluded initially, while 137 (38.5%) patients without available molecular data and 120 (33.7%) NPM1-negative/FLT3-ITD-negative patients were classified into the intermediate-risk group.